Advanced therapeutic candidates targeting neurodegenerative, neuromuscular, and central nervous system disorders. From target validation to commercial deployment.
Alzheimer's Disease (Early-Onset)
Parkinson's Disease (Non-Motor Symptoms)
Amyotrophic Lateral Sclerosis (ALS)
Diabetic Peripheral Neuropathy
Huntington's Disease
Treatment-Resistant Depression
Proprietary lipid nanoparticle and focused ultrasound platforms enabling precise CNS drug delivery with >400% increased penetration efficiency.
Wearable-integrated AI tracking motor, cognitive, and speech patterns to accelerate clinical trial endpoints by up to 60%.
Patient-derived cerebral organoids for rapid toxicology screening and disease modeling across neurodegenerative indications.